Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Holding DXCM?
Track your performance easily
DXCM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.34 - $142.00
Previous Close$72.38
Volume3.23M
Average Volume (3M)5.90M
Market Cap
$29.00B
Enterprise Value$30.60B
Total Cash (Recent Filing)$939.20M
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)44.6
Beta1.10
Next Earnings
Oct 24, 2024EPS Estimate
$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.62
Shares Outstanding400,726,824
10 Day Avg. Volume4,009,428
30 Day Avg. Volume5,902,819
Standard Deviation0.15
R-Squared0.16
Alpha0.00629
Financial Highlights & Ratios
Price to Book (P/B)11.92
Price to Sales (P/S)7.37
Price to Cash Flow (P/CF)26.00
P/FCF Ratio33.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.78
Enterprise Value/Gross Profit13.37
Enterprise Value/Ebitda29.65
Forecast
1Y Price Target
$96.19Price Target Upside32.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Dexcom News
PremiumMarket News
QQQ ETF Update, 10/16/2024 
PremiumMarket News
VOO ETF Update, 10/2/2024 
PremiumMarket News
SPY ETF Update, 10/1/2024 Bulls Say, Bears Say
Bulls Say
Market Potential And GrowthAmple white space available for continued CGM adoption across all segments of DXCM's core commercial opportunity in diabetes.
Product Accessibility And FeaturesDexcom's app can be downloaded on both iOS and Android devices, offering greater accessibility compared to Abbott, which is iOS only.
Product Launch And InnovationStelo launch ushers in a new era of non-prescription CGM for 125M non-insulin using T2D and pre-diabetics.
Bears Say
Market ShareNew patient starts in the U.S. fell below expectations due to market share loss.
Revenue GuidanceDXCM reported a rare topline miss and lowered its FY24 revenue guidance range.
Sales PerformanceA larger-than-expected decline in U.S. revenue per patient contributed to the underperformance.
---
Ownership Overview
0.47% Insiders
31.49% Mutual Funds
0.70% Other Institutional Investors
41.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $62.34 and its highest was $142.00 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Oct 24, 2024 which is in 2 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Jul 25, 2024. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.386 by $0.044.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.44.
How many shares outstanding does Dexcom have?
Dexcom has 400,726,840 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.43 in its last earnings report, beating expectations of $0.386. Following the earnings report the stock price went down -40.658%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 1B.
---
Dexcom Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.19 (32.47% Upside)
$96.19 (32.47% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 84%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 687.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.95%
12-Months-Change
Fundamentals
Return on Equity
29.41%
Trailing 12-Months
Asset Growth
-0.32%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DXCM Company Deck
---
DXCM Earnings Call
Q2 2024
0:00 / 0:00
---
DXCM Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$96.19
▲(32.47% Upside)
Technical Analysis
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
33/45 ratings generated profit
1 Year Average Return
+38.58%
reiterated a buy rating last month
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +38.58% per trade.
---